Nelson's syndrome is a rare condition now as a result of the advent of pituitary microsurgery for Cushing's disease. These tumours are rather invasive and need urgent treatment. Pituitary surgery is the first line treatment, although pituitary irradiation has been suggested as primary or secondary therapy.' Some tumours are not responsive and carry a poor prognosis. Somatostatin has been shown to be effective in the inhibition of adrenocorticotropin release by the cultured pituitary cells in a patient with Nelson's syndrome. 2 We decided to treat the patient by transsphenoidal microsurgery which is the first choice of therapy, but before surgery we administered octreotide to investigate its effectiveness in decreasing adrenocorticotropin secretion and tumour size. Before the administration of octreotide, blood samples for adrenocorticotropin detection were taken every 15 minutes for one hour in the morning between 8 and 9 am. The patient was then given octreotide at a dose of 100 jg tid subcutaneously for seven days, after which blood samples for adrenocorticotropin were again taken, as mentioned above. A second CT scan of the pituitary tumour was also taken (figure 2). The tumour was then successfully removed by the transsphenoidal route. Using immunohistochemical techniques the tumour was found to stain strongly for adrenocorticotropin but not for growth hormone, folliclestimulating hormone, luteinising hormone, or prolactin. Histopathologic and immunohistochemical examinations confirmed Nelson's syndrome.
Mean plasma adrenocorticotropin levels before and after octreotide therapy were 66.7 pmol/l and 36 pmol/l, respectively, a has been shown to be suppressed by octreotide in one patient. Visual field defects were improved after six weeks of treatment despite the absence of tumour shrinkage on CT scan and continued suppression of adrenocorticotropin levels was demonstrated over two years. 8 We think that variability in the concentrations of somatostatin receptors in adrenocorticotropinsecreting tumours may explain the variations in response to octreotide.
In our patient octreotide worked well and decreased adrenocorticotropin levels by at least 50% after seven days of treatment (100 ,ug tid). This fall in adrenocorticotropin levels may be related to the lack of negative feedback mechanism which was due to bilateral adrenalectomy, as adrenocorticotropin release by normal corticotrophs appears to be sensitive to somatostatin only in the absence of the physiological peripheral feedback regulation by glucocorticoids.'0
